Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate

Amgen Inc. (NASDAQ:AMGN) is one of the 10 best stocks to invest in during a recession.On February 27, 2026, Amgen Inc. (NASDAQ:AMGN)’s Phase 3 study (NCT05907122) saw an update. The study investigatin ...

Details:

• Published: 08/03/2026 17:47 (UTC)
• 📊 Characteristics Score:

  Asset Type: others Sentiment: -0.15 Entropy: 0.45 Relevance: 0.2 Staleness: 0.75 Uncertainty: 0.1 Level-1 Focus: asset-types Level-2 Focus: alternative-assets

• 🏷️ Tags: #amgen #biosimilar #abp 206 #opdivo #melanoma #phase 3 trial #wells fargo #biotechnology #tariffs

Source: https://rwatimes.io/articles/finviz-amgen-inc-amgn-completes-phase-3-trial-for-abp-206-opdivo-biosimilar-candidate-3715004744?utm_source=reddit&utm_medium=social&utm_campaign=reddit&utm_content=finviz-amgen-inc-amgn-completes-phase-3-trial-for-abp-206-opdivo-biosimilar-candidate-3715004744

Posted from RWA Times Bot